RVPH (Reviva Pharmaceuticals Holdings) Tariff Resilience Score: 7/10 (As of Jul. 06, 2026)


RVPH Reviva Pharmaceuticals Holdings Inc RVPH
22 GF Score
Price $0.66
! 1 Warning Sign
View Full Analysis

What is Reviva Pharmaceuticals Holdings Tariff Resilience Score?

Reviva Pharmaceuticals Holdings RVPH +0.36% 22 Tariff Resilience Score is 7 as of Jul. 06, 2026. GuruFocus rates RVPH with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 1,369 Biotechnology companies, Reviva Pharmaceuticals Holdings ranks better than 90.36% on this metric.

Reviva Pharmaceuticals Holdings has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Reviva Pharmaceuticals Holdings has Pharmaceuticals often have exemptions from tariffs, reducing vulnerability. Global supply chain dependencies exist, but the company has diversified suppliers. Sales are primarily in domestic markets, minimizing direct tariff impacts. Historical data shows limited impact from tariffs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Reviva Pharmaceuticals Holdings might have Highly Resilient.

Reviva Pharmaceuticals Holdings  (OTCPK:RVPH) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Reviva Pharmaceuticals Holdings Tariff Resilience Score Related Terms

RVPH vs AIM, BOLT, BRTX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reviva Pharmaceuticals Holdings Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's Tariff Resilience Score falls into.


RVPH
22GF Score
Reviva Pharmaceuticals Holdings Inc RVPH
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Reviva Pharmaceuticals Holdings (RVPH) has a Tariff Resilience Score of 7 as of Jul. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Reviva Pharmaceuticals Holdings ranks #132 out of 1369 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Reviva Pharmaceuticals Holdings' Tariff Resilience Score too high?
Reviva Pharmaceuticals Holdings' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Reviva Pharmaceuticals Holdings' value of 7 is 75% above this industry median. Based on the distribution chart, Reviva Pharmaceuticals Holdings ranks #132 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' Tariff Resilience Score compare to AIM and BOLT?
According to the Biotechnology industry distribution chart, Reviva Pharmaceuticals Holdings ranks #132 out of 1369 companies for Tariff Resilience Score. This places Reviva Pharmaceuticals Holdings in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Reviva Pharmaceuticals Holdings' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Reviva Pharmaceuticals Holdings's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Reviva Pharmaceuticals Holdings's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Reviva Pharmaceuticals Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current Tariff Resilience Score is 7 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Reviva Pharmaceuticals Holdings Business Description

Address 10080 North Wolfe Road, Suite SW3-200, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
22GF Score

Get the complete analysis for RVPH

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.66
Price